Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest
On 14 November 2025, Precigen, Inc. (NASDAQ: PGEN) is back in the spotlight. The gene‑therapy specialist’s stock is trading roughly 25–30% higher intraday around $4.90–$5.00, after closing at $3.86 on 13 November, on surging volume of nearly 11 million shares.